Drug Evaluation Committee Issues and Causes of Health Communication between Patients/Citizens and Pharmaceutical Companies
Data Science Subcommittee
June 2024
Communication of drug information to patients and the public is diversifying. Among them, various studies and efforts have been made on health communication involving pharmaceutical companies, but the satisfaction of patients and the public is still not high. Therefore, we conducted a survey and analysis of the causes of dissatisfaction among patients and the public, focusing on three areas of health communication between patients and pharmaceutical companies: (1) disease- and treatment-related information, (2) clinical trial-related information, and (3) patient and public involvement.
We hope that the results of this study will help to realize better health communication between patients/citizens and pharmaceutical companies in the future.
Japan Pharmaceutical Manufacturers Association, Committee on Drug Evaluation
Data Science Subcommittee 2023 Task Force 2-3
Deliverables of the Drug Evaluation Committee Return to list of all deliverables